Caisse DE Depot ET Placement DU Quebec grew its position in shares of Zoetis Inc (NYSE:ZTS) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 57,637 shares of the company’s stock after buying an additional 1,000 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Zoetis were worth $3,690,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of ZTS. Global X Management Co. LLC lifted its position in Zoetis by 10.3% during the second quarter. Global X Management Co. LLC now owns 10,340 shares of the company’s stock valued at $645,000 after purchasing an additional 969 shares during the period. Schwab Charles Investment Management Inc. raised its position in Zoetis by 6.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,595,919 shares of the company’s stock worth $99,554,000 after acquiring an additional 101,287 shares during the period. Advisors Asset Management Inc. raised its position in Zoetis by 9.5% in the second quarter. Advisors Asset Management Inc. now owns 14,131 shares of the company’s stock worth $881,000 after acquiring an additional 1,224 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in Zoetis by 0.9% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 446,874 shares of the company’s stock worth $27,876,000 after acquiring an additional 4,051 shares during the period. Finally, LMR Partners LLP bought a new position in Zoetis in the second quarter worth approximately $2,227,000. Institutional investors own 93.33% of the company’s stock.

Shares of Zoetis Inc (NYSE:ZTS) traded up $0.24 during midday trading on Monday, hitting $71.88. 1,640,000 shares of the stock were exchanged, compared to its average volume of 2,767,393. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The stock has a market capitalization of $35,030.00, a PE ratio of 32.97, a PEG ratio of 2.15 and a beta of 1.06. Zoetis Inc has a 1 year low of $50.57 and a 1 year high of $72.79.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 earnings per share. sell-side analysts expect that Zoetis Inc will post 2.37 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Thursday, November 9th were paid a $0.105 dividend. The ex-dividend date of this dividend was Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.58%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.

Several research firms have weighed in on ZTS. Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research report on Wednesday, November 29th. UBS reiterated a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Cowen set a $80.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, November 17th. Jefferies Group reiterated a “buy” rating on shares of Zoetis in a research report on Friday, November 10th. Finally, BMO Capital Markets increased their price target on shares of Zoetis from $65.00 to $70.00 and gave the stock a “market perform” rating in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $68.24.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/11/zoetis-inc-zts-stake-raised-by-caisse-de-depot-et-placement-du-quebec.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc and related stocks with our FREE daily email newsletter.